Cargando…
Identification of SEC61G as a Novel Prognostic Marker for Predicting Survival and Response to Therapies in Patients with Glioblastoma
BACKGROUND: The survival and therapeutic outcome vary greatly among glioblastoma (GBM) patients. Treatment resistance, including resistance to temozolomide (TMZ) and radiotherapy, is a great obstacle for these therapies. In this study, we aimed to evaluate the predictive value of SEC61G on survival...
Autores principales: | Liu, Bo, Liu, Jingping, Liao, Yuxiang, Jin, Chen, Zhang, Zhiping, Zhao, Jie, Liu, Kun, Huang, Hao, Cao, Hui, Cheng, Quan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
International Scientific Literature, Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6536036/ https://www.ncbi.nlm.nih.gov/pubmed/31094363 http://dx.doi.org/10.12659/MSM.916648 |
Ejemplares similares
-
Prognostic value of SEC61G in lung adenocarcinoma: a comprehensive study based on bioinformatics and in vitro validation
por: Zheng, Qunhao, et al.
Publicado: (2021) -
Identification of SEC61G as a Diagnostic and Prognostic Biomarker in Oral Squamous Cell Carcinoma
por: Zhang, Shi-Long, et al.
Publicado: (2023) -
Structure of the native Sec61 protein-conducting channel
por: Pfeffer, Stefan, et al.
Publicado: (2015) -
Loopy Sec61 mutants
por: LeBrasseur, Nicole
Publicado: (2005) -
SEC61G identified as a prognostic biomarker of head and neck squamous cell carcinoma
por: Shi, Yanan, et al.
Publicado: (2021)